VCL CB01

Drug Profile

VCL CB01

Alternative Names: ASP-0113; Cytomegalovirus DNA vaccine bivalent - Vical; TransVax

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Vical
  • Developer Astellas Pharma; Vical
  • Class Cytomegalovirus vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 19 Sep 2016 Adverse events data from a phase II trial in Cytomegalovirus infections (Prevention) released by Vical
  • 31 May 2016 Astellas Pharma completes a phase II trial for Cytomegalovirus infections (prevention, in CMV-seronegative patients receiving a kidney transplant from a CMV-seropositive donor) in USA, Australia, Canada, France, Germany and Spain (NCT01974206)
  • 09 May 2016 Vical plans to file a BLA application with the US FDA for Cytomegalovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top